--- title: "CONMED (CNMD) news: convertible notes, merger and buyback" url: "https://aibio.space/companies/conmed/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CNMD convertible notes, merger and buyback news: CONMED agrees to buy back 2.250% convertible notes due 2027 for cash." --- CNMD CONMED Corp NYSE · United States # CONMED (CNMD) news CNMD convertible notes, merger and buyback news Debt Financing · 2026-06-03 ## [CONMED agrees to buy back 2.250% convertible notes due 2027 for cash](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/) CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show. ## Latest CONMED news 1. 2026-05-27 Debt Financing [CONMED amends JPMorgan credit agreement to add a delayed draw term loan](https://aibio.space/news/conmed-amends-jpmorgan-credit-agreement-add-delayed-draw-term-loan/) The first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent. ## CONMED at a glance - **Ticker**: CNMD - **Listing**: NYSE - **Country**: United States - **Cash, Sep 30, 2026**: $48.0 million ### Related companies - [UFP TECHNOLOGIES INC](https://aibio.space/companies/ufp-technologies/) NASDAQ: UFPT - [United Health Products](https://aibio.space/companies/united-health-products/) OTC: UEEC - [Adastra Holdings](https://aibio.space/companies/adastra/) OTC: XTXXF - [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) NASDAQ: ANGO - [Innovative Eyewear](https://aibio.space/companies/innovative-eyewear/) NASDAQ: LUCY - [BIOADAPTIVES, INC.](https://aibio.space/companies/bioadaptives/) OTC: BDPT - [ENDRA Life Sciences](https://aibio.space/companies/endra-life-sciences/) NASDAQ: NDRA - [LUDWIG ENTERPRISES, INC.](https://aibio.space/companies/ludwig-enterprises/) OTC: LUDG ### Also on NYSE - [STERIS](https://aibio.space/companies/steris/) STE - [CHARLES RIVER LABORATORIES INTERNATIONAL, INC.](https://aibio.space/companies/charles-river-laboratories-international/) CRL - [ZIMMER BIOMET HOLDINGS, INC.](https://aibio.space/companies/zimmer-biomet/) ZBH - [Glass House Brands](https://aibio.space/companies/glass-house-brands/) GLAS - [Solventum](https://aibio.space/companies/solventum/) SOLV - [QIAGEN](https://aibio.space/companies/qiagen-n-v/) QGEN ## CONMED annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.37 billion](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | [$1.31 billion](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | | Research and development | [$55.9 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | [$54.4 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | | Net income (loss) | [$47.1 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | [$132.4 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | | Cash from operations | [$170.7 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | [$167.0 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000009/) | | Cash and equivalents | [$40.8 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000111/) | [$24.5 million](https://www.sec.gov/Archives/edgar/data/816956/000081695626000111/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $48.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CONMED Has CONMED sold convertible notes? Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/). Is CONMED involved in a merger or acquisition? Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/). Does CONMED have a share buyback? Our latest story on this, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/). What is the ticker symbol of CONMED? CONMED Corp trades under the ticker CNMD on NYSE. Where is CONMED listed? CONMED Corp is listed on NYSE. Which country or territory is CONMED listed under? Our directory records CONMED Corp under United States. Does aibio.space cover CONMED? aibio.space lists CONMED Corp among 2,820 public biotech companies and publishes its news here as stories appear. What was CONMED's revenue last year? $1.37 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is CONMED profitable? CONMED Corp reported net income of $47.1 million for the fiscal year ended Dec 31, 2025, and generated $170.7 million of cash from operations, per its annual report to the SEC. How much does CONMED spend on research and development? $55.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does CONMED have? $48.0 million in cash at Sep 30, 2026, per its 10-Q. What is the latest CONMED (CNMD) stock news? Our latest story on CONMED, dated Jun 3, 2026: "CONMED agrees to buy back 2.250% convertible notes due 2027 for cash". CONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show. [Source](https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/). How can I follow CONMED (CNMD) news? Press Follow on this page to add CONMED to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming CONMED so far, in Debt Financing. ## Investor discussion: CONMED Members talk about CONMED (CNMD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:CNMD on TradingView](https://www.tradingview.com/symbols/NYSE-CNMD/). ## Listing details CONMED Corp is a public biotech or pharmaceutical company listed on NYSE under the ticker CNMD, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CONMED Corp - **Ticker**: CNMD - **Listing**: NYSE - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/conmed/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CONMED (CNMD) news: convertible notes, merger and buyback", 2026-10-31, https://aibio.space/companies/conmed/